Total Payments
$3.4M
2024 Payments
$421,809
Companies
53
Transactions
4,660
Medicare Patients
2,659
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$2.6M (77.4%)
Consulting$361,738 (10.7%)
Travel$310,697 (9.2%)
Food & Beverage$75,568 (2.2%)
Research$9,242 (0.3%)
Education$7,403 (0.2%)
Gifts$3.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.2M | 910 | 63.6% |
| Honoraria | $462,346 | 221 | 13.7% |
| Consulting Fee | $361,738 | 178 | 10.7% |
| Travel and Lodging | $310,697 | 1,215 | 9.2% |
| Food and Beverage | $75,568 | 2,099 | 2.2% |
| Unspecified | $9,242 | 2 | 0.3% |
| Education | $7,403 | 33 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $6,284 | 1 | 0.2% |
| Gift | $3.00 | 1 | 0.0% |
Payments by Type
General
$3.4M
4,658 transactions
Research
$9,242
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $705,660 | 801 | $0 (2024) |
| US WorldMeds, LLC | $413,212 | 552 | $0 (2020) |
| ACADIA Pharmaceuticals Inc | $367,173 | 475 | $0 (2024) |
| MDD US Operations, LLC | $323,630 | 357 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $286,351 | 307 | $0 (2024) |
| Allergan, Inc. | $200,220 | 326 | $0 (2022) |
| ABBVIE INC. | $200,201 | 400 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $193,812 | 166 | $0 (2024) |
| Kyowa Kirin, Inc. | $155,469 | 179 | $0 (2024) |
| Acorda Therapeutics, Inc | $108,298 | 135 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $421,809 | 569 | Amneal Pharmaceuticals LLC ($78,311) |
| 2023 | $491,035 | 603 | Neurocrine Biosciences, Inc. ($105,592) |
| 2022 | $413,863 | 535 | Neurocrine Biosciences, Inc. ($112,212) |
| 2021 | $332,349 | 446 | Neurocrine Biosciences, Inc. ($74,642) |
| 2020 | $358,740 | 394 | US WorldMeds, LLC ($109,461) |
| 2019 | $511,318 | 732 | Neurocrine Biosciences, Inc. ($114,950) |
| 2018 | $445,293 | 743 | Neurocrine Biosciences, Inc. ($135,319) |
| 2017 | $410,195 | 638 | US WorldMeds, LLC ($146,468) |
All Payment Transactions
4,660 individual payment records from CMS Open Payments — Page 1 of 187
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Neuromodulation | ||||||
| 12/20/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: Musculoskeletal | ||||||
| 12/20/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| Category: Musculoskeletal | ||||||
| 12/20/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| Category: Musculoskeletal | ||||||
| 12/18/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Education | In-kind items and services | $3.40 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/17/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $3.92 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/16/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $7.47 | General |
| Category: NEUROLOGY | ||||||
| 12/15/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.63 | General |
| Category: Neuropsychiatry | ||||||
| 12/14/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $6.63 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,710.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $44.89 | General |
| Category: Neuropsychiatry | ||||||
| 12/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Neuropsychiatry | ||||||
| 12/09/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $98.62 | General |
| Category: AMANTADINE | ||||||
| 12/05/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: AMANTADINE | ||||||
| 12/05/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $2.19 | General |
| Category: AMANTADINE | ||||||
| 12/04/2024 | MDD US Operations, LLC | — | Consulting Fee | Cash or cash equivalent | $862.50 | General |
| 12/04/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,180.00 | General |
| 12/03/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $131.29 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/03/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: AMANTADINE | ||||||
| 12/02/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Central Nervous System | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 4, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE PERSISTENCE OF EFFECT AND SAFETY OF VALBENAZINE FOR THE TREATMENT OF TARDIVE DYSKINESIA | Neurocrine Biosciences, Inc. | $9,242 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 644 | 43,803 | $1.1M | $353,745 |
| 2022 | 19 | 678 | 46,883 | $1.1M | $367,971 |
| 2021 | 20 | 707 | 40,969 | $1.0M | $347,425 |
| 2020 | 17 | 630 | 41,712 | $968,037 | $316,805 |
Total Patients
2,659
Total Services
173,367
Medicare Billing
$1.4M
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 61 | 42,390 | $587,525 | $204,691 | 34.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 114 | 254 | $99,363 | $36,872 | 37.1% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 34 | 113 | $77,244 | $20,101 | 26.0% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 68 | 203 | $43,693 | $14,634 | 33.5% |
| 64646 | Injection of chemical for paralysis of nerve muscles on trunk, 1-5 muscles | Office | 2023 | 40 | 129 | $60,297 | $11,385 | 18.9% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2023 | 28 | 71 | $31,288 | $8,628 | 27.6% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2023 | 22 | 66 | $39,405 | $8,616 | 21.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 52 | 78 | $22,488 | $7,956 | 35.4% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 26 | 29 | $20,010 | $6,473 | 32.3% |
| 64643 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | Office | 2023 | 18 | 72 | $21,619 | $5,898 | 27.3% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 17 | 34 | $16,698 | $5,102 | 30.6% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2023 | 19 | 117 | $17,199 | $4,427 | 25.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $12,004 | $4,179 | 34.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 25 | 38 | $10,728 | $3,684 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 41 | $8,280 | $3,051 | 36.8% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 22 | 64 | $10,829 | $2,676 | 24.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 29 | 34 | $6,739 | $2,571 | 38.1% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Office | 2023 | 11 | 27 | $9,747 | $2,296 | 23.6% |
| 99422 | Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | Office | 2023 | 15 | 20 | $800.00 | $505.21 | 63.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 61 | 45,500 | $630,630 | $219,509 | 34.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 117 | 240 | $84,720 | $36,634 | 43.2% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 33 | 106 | $73,005 | $20,502 | 28.1% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 66 | 189 | $37,989 | $15,006 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 65 | 93 | $24,627 | $9,551 | 38.8% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2022 | 24 | 66 | $30,756 | $9,318 | 30.3% |
About Laxman Bahroo, D.O,
Laxman Bahroo, D.O, is a Neurology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1073761060.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Laxman Bahroo, D.O, has received a total of $3.4M in payments from pharmaceutical and medical device companies, with $421,809 received in 2024. These payments were reported across 4,660 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.2M).
As a Medicare-enrolled provider, Bahroo has provided services to 2,659 Medicare beneficiaries, totaling 173,367 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Washington, DC
- Active Since 09/03/2008
- Last Updated 02/24/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1073761060
Products in Payments
- INGREZZA (Drug) $625,661
- NUPLAZID (Drug) $360,574
- APOKYN (Drug) $297,790
- BOTOX (Biological) $268,435
- RYTARY (Drug) $257,008
- GOCOVRI (Drug) $146,403
- Dysport (Drug) $122,531
- MYOBLOC (Biological) $116,172
- INBRIJA (Drug) $107,904
- Xadago (Drug) $100,065
- NOURIANZ (Drug) $95,691
- Duopa (Drug) $87,347
- AUSTEDO (Drug) $72,511
- Gocovri (Drug) $62,712
- Nourianz (Drug) $59,671
- ONGENTYS (Drug) $49,641
- DYSPORT (Drug) $45,624
- MYOBLOC (Drug) $43,393
- NORTHERA (Drug) $42,483
- APTIOM (Drug) $34,024
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Washington
Dr. Fahd Amjad, Md, MD
Neurology — Payments: $2.4M
Neurology $2.4M
Jessica Ailani, Md, MD
Neurology — Payments: $1.3M
Neurology $1.3M
Fernando Pagan
Neurology — Payments: $1.1M
Neurology $1.1M
Dr. Yasar Torres-Yaghi, M.d, M.D
Neurology — Payments: $868,293
Neurology $868,293
Benjamin Osborne
Neurology — Payments: $770,154
Neurology $770,154
Dr. Faria Amjad, Md, MD
Neurology — Payments: $671,517
Neurology $671,517